Atara Biotherapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $516 | $1,595 | $3,453 | $17,575 |
Gross Profit | 392 | 1,491 | 3,338 | 17,021 |
EBITDA | -3,340 | -2,463 | -3,330 | 3,598 |
EBIT | -3,369 | -2,512 | -3,366 | 3,362 |
Net Income | -4,145 | -3,406 | -4,303 | 2,387 |
Net Change In Cash | 516 | 1,595 | 3,453 | 17,575 |
Free Cash Flow | -3,073 | -5,697 | -9,787 | -7,318 |
Cash | 8,360 | 8,482 | 5,742 | 16,903 |
Basic Shares | 14,081 | 12,718 | 13,564 | 12,310 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $120,772 | $128,940 | $8,573 | $63,573 |
Gross Profit | 99,560 | 107,931 | -313 | 63,573 |
EBITDA | 38,627 | -75,749 | -265,997 | -222,264 |
EBIT | 36,511 | -80,800 | -270,826 | -227,917 |
Net Income | 32,688 | -85,403 | -276,126 | -228,302 |
Net Change In Cash | 120,772 | 128,940 | 8,573 | 63,573 |
Cost of Revenue | -14,390 | |||
Free Cash Flow | -50,940 | -68,963 | -194,200 | -274,623 |
Cash | 8,482 | 25,030 | 25,841 | 92,942 |
Basic Shares | 12,718 | 7,488 | 4,236 | 4,079 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.29 |
2025-12-31 | -$0.35 |
2025-09-30 | -$0.32 |
2025-06-30 | $0.19 |